Free Trial
ETR:MDG1

Medigene (MDG1) Stock Price, News & Analysis

Medigene logo

About Medigene Stock (ETR:MDG1)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
€0.19
€1.86
52-Week Range
N/A
Volume
63,357 shs
Average Volume
306,207 shs
Market Capitalization
$1.45 million
P/E Ratio
N/A
Dividend Yield
1.31%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

MDG1 Stock News Headlines

2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
See More Headlines

MDG1 Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ETR:MDG1
CIK
N/A
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
7.12
Net Income
$-4,667,238.14
Net Margins
-249.83%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.87 million
Price / Cash Flow
1.37
Book Value
€0.72 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.45 million
Optionable
Not Optionable
Beta
0.84
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (ETR:MDG1) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners